Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
World J Urol ; 41(4): 1069-1075, 2023 Apr.
Article in English | MEDLINE | ID: covidwho-2278876

ABSTRACT

PURPOSE: To describe the incidence, management, and survival outcomes of patients with muscle-invasive urothelial carcinoma (MIUC) undergoing radical surgery (RS) in France. METHODS: We relied on a non-interventional real-world retrospective study based on French National Hospitalization Database. Adults with MIUC with a first RS between 2015 and 2020 were selected. Subpopulations of patients with RS performed in 2015 and 2019 (pre-COVID-19) were extracted, according to cancer site: muscle-invasive bladder cancer (MIBC) or upper tract urothelial carcinoma (UTUC). Disease-free and overall survival (DFS, OS - Kaplan-Meier) were assessed on the 2015 subpopulation. RESULTS: Between 2015 and 2020, 21,295 MIUC patients underwent a first RS. Of them, 68.9% had MIBC, 28.9% UTUC, and 2.2% both cancers. Apart from fewer men among UTUC (70.2%) than MIBC patients (90.1%), patients' demographic (mean age ~ 73 years) and clinical characteristics were similar whatever the cancer site or year of first RS. In 2019, RS alone was the most frequent treatment, occurring in 72.3% and 92.6% in MIBC and UTUC, respectively. Between 2015 and 2019, neoadjuvant use rate increased from 13.8% to 22.2% in MIBC, and adjuvant use rate increased from 3.7% to 6.3% in UTUC. Finally, median [95% confidence interval] DFS times were 16.0 [14.0-18.0] and 27.0 [23.0-32.0] months among MIBC and UTUC, respectively. CONCLUSION: Among patients with resected MIUC annually, RS alone remained the main treatment. Neoadjuvant and adjuvant use increased between 2015 and 2019. Nonetheless, MIUC remains of poor prognosis, highlighting an unmet medical need, notably among patients at high risk of recurrence.


Subject(s)
COVID-19 , Carcinoma, Transitional Cell , Urinary Bladder Neoplasms , Male , Adult , Humans , Aged , Urinary Bladder Neoplasms/pathology , Carcinoma, Transitional Cell/pathology , Retrospective Studies , Muscles
2.
Frontiers in surgery ; 9, 2022.
Article in English | EuropePMC | ID: covidwho-2073343

ABSTRACT

Purpose The COVID-19 pandemic has led to competing strains on hospital resources and healthcare personnel. Patients with newly diagnosed invasive urothelial carcinomas of bladder (UCB) upper tract (UTUC) may experience delays to definitive radical cystectomy (RC) or radical nephro-ureterectomy (RNU) respectively. We evaluate the impact of delaying definitive surgery on survival outcomes for invasive UCB and UTUC. Methods We searched for all studies investigating delayed urologic cancer surgery in Medline and Embase up to June 2020. A systematic review and meta-analysis was performed. Results We identified a total of 30 studies with 32,591 patients. Across 13 studies (n = 12,201), a delay from diagnosis of bladder cancer/TURBT to RC was associated with poorer overall survival (HR 1.25, 95% CI: 1.09–1.45, p = 0.002). For patients who underwent neoadjuvant chemotherapy before RC, across the 5 studies (n = 4,316 patients), a delay between neoadjuvant chemotherapy and radical cystectomy was not found to be significantly associated with overall survival (pooled HR 1.37, 95% CI: 0.96–1.94, p = 0.08). For UTUC, 6 studies (n = 4,629) found that delay between diagnosis of UTUC to RNU was associated with poorer overall survival (pooled HR 1.55, 95% CI: 1.19–2.02, p = 0.001) and cancer-specific survival (pooled HR of 2.56, 95% CI: 1.50–4.37, p = 0.001). Limitations included between-study heterogeneity, particularly in the definitions of delay cut-off periods between diagnosis to surgery. Conclusions A delay from diagnosis of UCB or UTUC to definitive RC or RNU was associated with poorer survival outcomes. This was not the case for patients who received neoadjuvant chemotherapy.

3.
Eur Urol Open Sci ; 37: 73-79, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1633993

ABSTRACT

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has greatly affected health care priorities. OBJECTIVE: To explore and analyse trends in public online search for urological cancers. DESIGN SETTING AND PARTICIPANTS: We performed a retrospective analysis using the Google Health Trends online tool. Data related to urological cancer terms ("prostate cancer", "kidney cancer", and "bladder cancer") were extracted. We analysed trends for the whole world and for five countries: Italy, the UK, France, Sweden, and the USA. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A join-point regression model was used to define significant changes in trends over time. Week percentage changes (WPCs) were estimated to summarise linear trends. The Mann-Whitney test was used to compare the search volume during the COVID-19 pandemic period (from January 2020 to April 2021) and the equivalent period of 2018 and 2019. RESULTS AND LIMITATIONS: During COVID-19, worldwide online interest decreased significantly for all urological cancers, especially prostate cancer (WPC: -13.9%, p = 0.004; WPC: -5.4%, p < 0.001; and WPC: -4.3%, p < 0.001, for prostate, kidney, and bladder cancers, respectively). The most important decline was observed in the USA. The interest for all cancers was significantly less during the COVID-19 pandemic than in the same periods of 2018 and 2019. CONCLUSIONS: Online interest in urological cancers decreased significantly during the COVID-19 pandemic. Future studies will tell us whether this will translate into worse oncological outcomes. PATIENT SUMMARY: Patients are increasingly searching the Internet to get information on cancer. We explored Google queries during the COVID-19 pandemic and found that online interest decreased significantly for all urological cancers, especially prostate cancer. We do not know yet whether this will translate into worse prognosis for patients.

6.
J Robot Surg ; 15(6): 937-944, 2021 Dec.
Article in English | MEDLINE | ID: covidwho-1053073

ABSTRACT

The COVID-19 pandemic led to a decrease in surgical activity to avoid nosocomial contamination. Robotic-assisted surgery safety is uncertain, since viral dissemination could be facilitated by gas environment. We assessed the impact and safety of the COVID-19 pandemic on robotic-assisted surgery. Data were collected prospectively during lockdown (March 16th-April 30th 2020) in 10 academic centres with robotic surgical activity and was compared to a reference period of similar length. After surgery, patients with suspected COVID-19 were tested by RT-PCR. During the COVID-19 lockdown we evidenced a 60% decrease in activity and a 49% decrease in oncological procedures. However, the overall proportion of oncological surgeries was significantly higher during the pandemic (p < 0.001). Thirteen (7.2%) patients had suspected COVID-19 contamination, but only three (1.6%) were confirmed by RT-PCR. The COVID-19 pandemic resulted in a significant decrease in robotic-assisted surgery. Robotic approach was safe with a low rate of postoperative COVID-19 contamination.


Subject(s)
COVID-19 , Robotic Surgical Procedures , Communicable Disease Control , Humans , Pandemics , Robotic Surgical Procedures/methods , SARS-CoV-2
8.
Urol Oncol ; 39(5): 298.e7-298.e11, 2021 05.
Article in English | MEDLINE | ID: covidwho-779731

ABSTRACT

OBJECTIVES: To assess potential nosocomial coronavirus disease-2019 (COVID-19) transmission in patients who underwent robot-assisted laparoscopic procedures during the pandemic. MATERIAL AND METHODS: Prospective study in patients undergoing robot-assisted laparoscopy in urology or gynaecology within 2 academic hospitals. Patients underwent local preoperative COVID-19 screening using a symptoms questionnaire. Patients with suspicious screening underwent coronavirus real time-polymerase chain reaction (RT-PCR) and were excluded from robotic surgery if positive. Patients with symptoms postsurgery were systematically tested for coronavirus by RT-PCR. One-month postsurgery, all patients had a telephone consultation to evaluate COVID-19 symptoms. RESULTS: Sixty-eight patients underwent robotic surgery during the study period (median age: 63-years [IQR: 53-70], 1.8 male: female ratio). Oncology was the main indication for robotic surgery (n = 62, 91.2%) and 26 patients (38.2%) received a chest CT-scan prior to surgery. Eleven patients (16.2%) were symptomatic after surgery of whom only 1 tested positive for coronavirus by RT-PCR (1.5%) and was transferred to COVID-19 unit with no life-threatening condition. No attending surgeon was diagnosed with COVID-19 during the study. CONCLUSIONS: Robot-assisted laparoscopic surgery seemed safe in the era of COVID-19 as long as all recommended precautions are followed. The rate of nosocomial COVID-19 transmission was extremely low despite the fact that we only used RT-PCR testing in symptomatic patients during the preoperative work-up. Larger cohort is needed to validate these results.


Subject(s)
COVID-19/transmission , Cross Infection/diagnosis , Robotic Surgical Procedures/methods , SARS-CoV-2/isolation & purification , Surveys and Questionnaires/statistics & numerical data , Academic Medical Centers , Aged , COVID-19/epidemiology , COVID-19/virology , Female , Gynecologic Surgical Procedures/methods , Gynecologic Surgical Procedures/statistics & numerical data , Humans , Laparoscopy/methods , Male , Middle Aged , Pandemics/prevention & control , Postoperative Period , Prospective Studies , Robotic Surgical Procedures/statistics & numerical data , SARS-CoV-2/physiology , Urologic Surgical Procedures/methods , Urologic Surgical Procedures/statistics & numerical data
9.
World J Urol ; 39(6): 1991-1996, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-754594

ABSTRACT

PURPOSE: Lockdown during the COVID-19 pandemic compelled urologists to change access to healthcare, especially for oncology patients. Teleconsultation is a safe way to receive medical advice without a risk of infection, and was implemented urgently in our academic centres. Our purpose was to evaluate patient and physician satisfaction with teleconsultation set up during the COVID-19 pandemic. METHODS: From March 16th 2020, all face-to-face consultations were cancelled in France, except for emergencies. Teleconsultation was started immediately by five senior urologists in two academic hospitals. All patients received an email survey including the validated Teleconsultation Satisfaction Questionnaire (TSQ) and demographic questions. Data were collected prospectively. Physicians also responded to the TSQ. Patient satisfaction was measured objectively with the validated 14-item TSQ. Each item was scored on a 5-point Likert scale. Factors associated with positive satisfaction with teleconsultation were assessed by multivariable logistic regression. RESULTS: Overall, 105 patients replied to the survey (91.3%). Median age was 66 years (IQR: 55‒71) and 95 were men (90.5%). Median overall TSQ score was 67 (IQR: 60‒69); teleconsultation was judged to be a good experience by 88 patients (83.8%) and four physicians (80%). Patients who met their surgeon for the first time were more likely to have a good experience (OR = 1.2 [95% CI 1.1‒1.5], p = 0.03). CONCLUSION: Introduced rapidly during the COVID-19 lockdown, urology teleconsultation attained a high level of satisfaction among both patients and physicians. A major change in telemedicine use is foreseen in the post COVID-19 era.


Subject(s)
Attitude of Health Personnel , COVID-19 , Patient Preference/statistics & numerical data , Remote Consultation , Urologic Diseases , Urology Department, Hospital , Aged , COVID-19/epidemiology , COVID-19/prevention & control , Communicable Disease Control/organization & administration , Female , France/epidemiology , Humans , Male , Organizational Innovation , Remote Consultation/methods , Remote Consultation/standards , Remote Consultation/statistics & numerical data , Risk Adjustment/methods , SARS-CoV-2 , Surveys and Questionnaires , Urologic Diseases/diagnosis , Urologic Diseases/epidemiology , Urologic Diseases/therapy , Urology Department, Hospital/organization & administration , Urology Department, Hospital/trends
10.
BJU Int ; 126(4): 436-440, 2020 10.
Article in English | MEDLINE | ID: covidwho-703610
13.
Eur Urol ; 78(1): 21-28, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-125264

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic is unlike anything seen before by modern science-based medicine. Health systems across the world are struggling to manage it. Added to this struggle are the effects of social confinement and isolation. This brings into question whether the latest guidelines are relevant in this crisis. We aim to support urologists in this difficult situation by providing tools that can facilitate decision making, and to minimise the impact and risks for both patients and health professionals delivering urological care, whenever possible. We hope that the revised recommendations will assist urologist surgeons across the globe to guide the management of urological conditions during the current COVID-19 pandemic.


Subject(s)
Betacoronavirus , Coronavirus Infections/epidemiology , Disease Management , Pneumonia, Viral/epidemiology , Practice Guidelines as Topic , Societies, Medical , Urologic Diseases/therapy , Urology/standards , COVID-19 , Coronavirus Infections/complications , Europe , Humans , Pandemics , Pneumonia, Viral/complications , SARS-CoV-2 , Urologic Diseases/complications , Urologic Diseases/diagnosis
14.
Eur Urol ; 78(1): 1-3, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-116508

ABSTRACT

Non-muscle-invasive bladder cancer patients with COVID-19 are more likely to develop acute respiratory distress syndrome. Thus, several adjustments to the use of intravesical instillations of bacillus Calmette-Guérin should be made during the current pandemic to limit the risk of contamination.


Subject(s)
BCG Vaccine/administration & dosage , Betacoronavirus , Coronavirus Infections/complications , Pandemics , Pneumonia, Viral/complications , Urinary Bladder Neoplasms/drug therapy , Adjuvants, Immunologic/administration & dosage , Administration, Intravesical , Aged , COVID-19 , Coronavirus Infections/epidemiology , Disease Progression , Drug Administration Schedule , Female , Humans , Male , Neoplasm Invasiveness , Pneumonia, Viral/epidemiology , SARS-CoV-2 , Urinary Bladder Neoplasms/complications , Urinary Bladder Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL